Latest Factor VII Stories
WHIPPANY, N.J., Dec. 17, 2014 /PRNewswire/ -- Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S.
SAN FRANCISCO, December 7, 2014 /PRNewswire/ -- Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
PLAINSBORO, N.J., Dec.
Just Released Results from Innovaacom Program Show 94% of Physicians More Confident Treating and Communicating Best Practices for Hemophilia Atlanta, Georgia
- Three-year findings regarding prophylaxis versus on-demand treatment in adults with hemophilia A WHIPPANY, N.J., Sept.
Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug.
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
- In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.